北卡罗来纳州社区医院晚期非小细胞肺癌分子生物标志物及PD-L1检测现状
该研究基于北卡罗来纳州38家社区医院389份IV期NSCLC病理报告,评估分子标志物和PD-L1检测率及社会人口学差异。结果显示非鳞癌分子检测率64.4%,所有患者PD-L1检测率53.2%,检测率在社会人口学因素间无显著差异,但家庭互联网接入较高地区患者更可能接受PD-L1检测。
要点
- 社区医院晚期NSCLC分子检测和PD-L1检测使用不足。
- 非鳞癌分子检测率64.4%,所有NSCLC患者PD-L1检测率53.2%。
- 家庭互联网接入较高地区患者更可能接受PD-L1检测(aOR=1.66)。
核心结论
- 生物标志物检测在NSCLC中仍使用不足,需扩大人群并评估医院特异性检测方案以解决障碍。
研究设计与样本
- 回顾性研究,纳入北卡罗来纳州38家社区医院389份IV期NSCLC病理报告,提取人口学、组织学、分子及PD-L1检测结果,并地理编码分析行程时间和区域变量。
主要发现
- 非鳞癌NSCLC患者分子标志物检测率为64.4%,所有NSCLC患者PD-L1检测率为53.2%。
- 社会人口学因素与分子标志物检测率差异无统计学意义。
- 家庭互联网接入较高地区患者更可能接受PD-L1检测(调整OR=1.66,95%CI 1.02-2.71)。
临床怎么用
- 社区实践中应提高对晚期NSCLC患者指南推荐的分子标志物和PD-L1检测的认识与实施。
局限性
- 样本量有限,仅来自北卡罗来纳州社区医院,可能限制普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Precision medicine in advanced non-small cell lung cancer (NSCLC) requires molecular biomarker testing in patients with nonsquamous and select patients with squamous histologies, and programmed death-ligand 1 (PD-L1) testing in both. RESEARCH QUESTION: What are rates of molecular and PD-L1 biomarker testing in patients with advanced NSCLC in community practices, and do rates vary by sociodemographic factors? What is the prevalence of molecular biomarker mutations and PD-L1 expression levels? STUDY DESIGN AND METHODS: From 389 stage IV NSCLC pathology reports obtained through the University of North Carolina Lineberger Comprehensive Cancer Center's Rapid Case Ascertainment Program from 38 community hospitals across North Carolina, we abstracted demographics, histology, molecular biomarker testing and results, and PD-L1 testing and expression. We geocoded patient and hospital addresses to determine travel time, distance to care, and census block level contextual variables. We compared molecular biomarker and PD-L1 testing rates, the prevalence of molecular biomarkers, and PD-L1 expression levels by race and sex, using χ2 tests. We determined predictors of testing, using multivariable logistic regression and report adjusted ORs and 95%CI. RESULTS: Among patients with nonsquamous NSCLC, 64.4% were tested for molecular biomarkers, and among all NSCLC patients 53.2% were tested for PD-L1 expression. Differences in biomarker testing rates by sociodemographic factors were not statistically significant in univariate or adjusted analyses. Adjusted analyses showed that patients living in areas with higher household internet access were more likely to undergo PD-L1 testing (adjusted OR = 1.66, 95% CI, 1.02-2.71). Sociodemographic differences in molecular biomarker prevalence and PD-L1 expression levels were not statistically significant, except for human epidermal growth factor receptor 2 (HER2) mutations, which occurred in 16.7% of males vs 0% in females, P = .05. INTERPRETATION: Biomarker testing remains underused in NSCLC. Future work should include larger populations and evaluate hospital-specific testing protocols to identify and address barriers to guideline-recommended testing.
引用
- Rivera MP, Charlot M, Durham DD, et al. Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals. Chest. 2021. PMID: 33887243. doi:10.1016/j.chest.2021.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。